Abstract
Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Significant antibody production is observed; however, whether this is protective or pathogenic remains to be determined. Defining the immunopathological changes in patients with COVID-19 provides potential targets for drug discovery and is important for clinical management.
MeSH terms
- Antibodies, Monoclonal, Humanized / therapeutic use
- Antiviral Agents / therapeutic use
- COVID-19
- COVID-19 Serotherapy
- Clinical Trials as Topic
- Coronavirus Infections / immunology*
- Coronavirus Infections / pathology*
- Coronavirus Infections / therapy
- Cytokines / immunology
- Humans
- Immunization, Passive
- Inflammation / pathology
- Mesenchymal Stem Cell Transplantation
- Pandemics
- Pneumonia, Viral / immunology*
- Pneumonia, Viral / pathology*
- Pneumonia, Viral / therapy
Substances
- Antibodies, Monoclonal, Humanized
- Antiviral Agents
- Cytokines
- tocilizumab